Rocket Pharmaceuticals, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against RCKT

SAN DIEGO, June 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 7, 2025 and May 26, 2025. Rocket is a fully integrated, late-stage biotechnology company focused on the development of gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.For more information, submit a form, ...